Reference | </br>1:Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies. Bugarski-Kirola D, Blaettler T, Arango C, Fleischhacker WW, Garibaldi G, Wang A, Dixon M, Bressan RA, Nasrallah H, Lawrie S, Napieralski J, Ochi-Lohmann T, Reid C, Marder SR.Biol Psychiatry. 2016 Dec 15. pii: S0006-3223(16)33109-2. doi: 10.1016/j.biopsych.2016.11.014. [Epub ahead of print] PMID: 28117049 </br>2:Efficacy and Safety of Bitopertin in Patients with Schizophrenia and Predominant Negative Symptoms: Subgroup Analysis of Japanese Patients from the Global Randomized Phase 2 Trial. Hirayasu Y, Sato SI, Shuto N, Nakano M, Higuchi T.Psychiatry Investig. 2017 Jan;14(1):63-73. doi: 10.4306/pi.2017.14.1.63. Epub 2016 Dec 29. PMID: 28096877 Free PMC Article</br>3:Bitopertin in schizophrenia: glass half full? Javitt DC.Lancet Psychiatry. 2016 Dec;3(12):1092-1093. doi: 10.1016/S2215-0366(16)30354-6. Epub 2016 Nov 2. No abstract available. PMID: 27816569 </br>4:Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme. Bugarski-Kirola D, Iwata N, Sameljak S, Reid C, Blaettler T, Millar L, Marques TR, Garibaldi G, Kapur S.Lancet Psychiatry. 2016 Dec;3(12):1115-1128. doi: 10.1016/S2215-0366(16)30344-3. Epub 2016 Nov 2. PMID: 27816567 </br>5:Effects of the glycine reuptake inhibitors bitopertin and RG7118 on glycine in cerebrospinal fluid: results of two proofs of mechanism studies in healthy volunteers. Hofmann C, Pizzagalli F, Boetsch C, Alberati D, Ereshefsky L, Jhee S, Patat A, Boutouyrie-Dumont B, Martin-Facklam M.Psychopharmacology (Berl). 2016 Jul;233(13):2429-39. doi: 10.1007/s00213-016-4317-7. Epub 2016 May 14. PMID: 27178435 </br>6:A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia. Hirayasu Y, Sato S, Takahashi H, Iida S, Shuto N, Yoshida S, Funatogawa T, Yamada T, Higuchi T.BMC Psychiatry. 2016 Mar 15;16:66. doi: 10.1186/s12888-016-0778-9. PMID: 26980460 Free PMC Article</br>7:Combining /’Bottom-Up/’ and /’Top-Down/’ Methods to Assess Ethnic Difference in Clearance: Bitopertin as an Example. Feng S, Shi J, Parrott N, Hu P, Weber C, Martin-Facklam M, Saito T, Peck R.Clin Pharmacokinet. 2016 Jul;55(7):823-32. doi: 10.1007/s40262-015-0356-1. PMID: 26715215 Free PMC Article</br>8:Effects of Cytochrome P450 3A4 Inhibitors-Ketoconazole and Erythromycin-on Bitopertin Pharmacokinetics and Comparison with Physiologically Based Modelling Predictions. Boetsch C, Parrott N, Fowler S, Poirier A, Hainzl D, Banken L, Martin-Facklam M, Hofmann C.Clin Pharmacokinet. 2016 Feb;55(2):237-47. doi: 10.1007/s40262-015-0312-0. PMID: 26341813 </br>9:Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin. Rofail D, Regnault A, le Scouiller S, Berardo CG, Umbricht D, Fitzpatrick R.Qual Life Res. 2016 Jan;25(1):201-11. doi: 10.1007/s11136-015-1057-9. Epub 2015 Jul 5. PMID: 26143058 </br>10:Physiologically based absorption modelling to predict the impact of drug properties on pharmacokinetics of bitopertin. Parrott N, Hainzl D, Scheubel E, Krimmer S, Boetsch C, Guerini E, Martin-Facklam M.AAPS J. 2014 Sep;16(5):1077-84. doi: 10.1208/s12248-014-9639-y. Epub 2014 Jun 27. PMID: 24970349 Free PMC Article
|